Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of our work was to address if pyrotinib treatment impacts the effect of HER2-positive GC cell-derived exosomes on endothelial cell (EC) progression.
|
31114227 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
|
31587095 |
2019 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, intratumoral heterogeneity of HER2 expression is observed in 52% of metastatic GC cases.
|
31022472 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression level of miR-143 was down-regulated in GC cell lines, including HER2-positive GC cell lines, MKN7, and KATO-III.
|
30959742 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
|
30535535 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Upon analysis, we found a low positive predictive value of an individual morphologic pattern for biomarker-expression, indicating that an individual morphologic pattern alone cannot predict PD-L1, Her2/neu expression and EBV- or MSI-gastric cancer.
|
31676362 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
|
30927036 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Trastuzumab, an anti-human epidermal growth factor type 2 (HER2) monoclonal antibody, is effective in HER2-positive stomach cancer.
|
29992451 |
2019 |
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The SNPs rs2643194, rs2934971, and rs1058808 of the ERBB2 gene were associated with increased risk for GC.
|
31116314 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions.
|
30711995 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer is a major challenge.
|
31423245 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dual block HER2 assessment can effectively increase the HER2 positive rate in resected specimens of gastric cancer (GC).
|
31739285 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We studied the plasma human epidermal growth factor receptor 2 (HER2) amplification in gastric cancer (GC) patients by droplet digital PCR (ddPCR) during therapy with trastuzumab.
|
30838039 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We herein reported a case of a 54-year-old male patient who was initially diagnosed with HER2-negative advanced gastric cancer.
|
31571920 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate the real effects of fixation conditions on HER-2 testing or PD-L1 testing for gastric cancer using gastrectomy specimens.
|
30842953 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: CT-P6 (trastuzumab-pkrb, Herzuma) is a trastuzumab biosimilar approved for use in HER2 positive breast cancer and HER2 positive gastric cancer.
|
31507219 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER-2 is one of the key targets for the gastric cancer therapy.
|
31277667 |
2019 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated a positive prognostic impact of HER2 overexpression in a large cohort of EAC, contrary to other solid malignancies including gastric cancer and breast cancer, but consistent to the results of a large study on EAC from 2012.
|
30621632 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
|
31102009 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2+ GCs were related to male gender (p = 0.007), intestinal type (p = 0.001) and less advanced pTNM stage (p = 0.029).
|
31595457 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
|
30328533 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial.
|
30463072 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in <i>HER2</i>-Amplified Gastric Cancer.
|
30504425 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
|
31423428 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
VIR and CC-IR expressions are frequent in GC, biologically significant and even correlate with the HER2 status, opening avenues for novel putative therapeutic interventions in GC.
|
30989432 |
2019 |